ArticleDiscover oncology2026
Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMET exon 14 skipping (METex14) mutations account for 1-3% of non-small cell lung cancer (NSCLC) cases. Although MET tyrosine kinase inhibitors (TKIs) and immunotherapy have improved survival, resistance remains a challenge.
methodsThis real-world analysis includes 24 METex14-mutated NSCLC patients who underwent genetic sequencing before MET TKI treatment. RNA sequencing data from 11 METex14 mutated NSCLC patients in the TCGA database were analyzed to characterize tumor immune microenvironment composition and functional profiles. Patient-derived organoids (PDOs) were established from malignant effusion or tissue of three patients to suggest treatment responses.
resultsIn this cohort of 24 METex14-mutated NSCLC patients, the overall median progression-free survival (mPFS) was 7.0 months. While crizotinib (n = 12) showed mPFS of 6.1 months (disease control rate DCR 66.7%) with 50% progressing within 3 months, vebreltinib (n = 12) demonstrated longer mPFS of 8.7 months (DCR 91.7%), with half exceeding 7.0 months. However, these differences did not reach statistical significance. Notably, two patients benefited from sequential type Ib MET TKI therapy after type Ia failure. Resistance mechanisms included acquired D1228N MET mutation, EGFR amplification, and histologic transformation to pulmonary sarcomatoid carcinoma (n = 1). One patient with high PD-L1 expression (TPS ≥ 50%) achieved 13.0 months PFS with camrelizumab/endostar immunotherapy. RNA sequencing revealed PD-L1-high tumors harbored an immune-favorable microenvironment. Patient-derived organoid (PDO) drug test demonstrated preliminary qualitative consistency with clinical outcomes, supporting their predictive value.
conclusionsWhile vebreltinib appears clinically advantageous over crizotinib for METex14-mutated NSCLC, the therapeutic benefits did not reach statistical significance in this study. The observed differential response patterns and resistance mechanisms suggest distinct biological behaviors to type Ia and Ib MET TKIs that warrant further investigation. These findings underscore the need for larger prospective studies to validate the potential superiority of vebreltinib and to better characterize the molecular determinants in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.